Note: Earnings Estimate for Calendar 2009 is 0.14; based on calendar in coverage being overly optimistic, my personal hope is that AEMD will earn 0.00-0.05 for calendar 2009
1. Notification on potential award from Bill and Melinda Gates Foundation (DONE)
Note: AEMD did not get this Round 2 grant, largely because the objective identified in the grant application was acheived by the company in India before the Gates Foundation even made a decision on whether or not to award AEMD a grant. The Gates Foundation encouraged AEMD to refine the application and resubmit it for Round 3.
May/June:
1. Notification on potential 5-year contract award from BARDA/fed gov
2. Release of Annual Report
3. Completion of GMP Manufacturing and Quality Systems to allow commerical export
Other 2009 Milestones (targeted month unknown):
1. Announcment of agreement to treat Dengue Fever in India
5. Initiation of commerical production for sale of product in India
6. Starting of clinical trials in U.S. involving 10-patient safety study mimicing what has already been conducted in India (Described by CEO as near-term objective at RedChip Conference)
7. Define regulatory and commericalization plan for European Union
8. Complete currently ongoing in-vitro Cytomegalovirus study
9. Announce research plan and progress to concetnrate and subsequently identify new viruses underlying specific diseases and identify biomarkers that can be targetes for drug intervention.
10. Announce research progress to advance adjunct cancer treatment possibilities. (Creation of wholly owned subsidiary Exosome Sciences - DONE)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.